RNAZ

+ Watchlist + Portfolio

TransCode Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.55
52-Week Range: $1.52 – $20.99
Market Cap: $26.58M
P/E (TTM): —
EPS (TTM): -52.06
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -59.28%
Return on Assets: -19.90%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.97
Debt/Equity: 0.00
Total Debt: $652.41K
Free Cash Flow: $-13.78M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $184.90M

RNAZ Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$10.23M	$12.26M	$9.71M	$13.42M
Selling, General & Admin	$8.40M	$7.15M	$5.95M	$5.77M
Operating Expenses	$17.55M	$18.50M	$15.14M	$17.92M
Operating Income	-$17.55M	-$18.50M	-$15.14M	-$17.92M
EBITDA	-$17.43M	-$17.97M	-$16.19M	-$34.31M
Pretax Income	-$17.56M	-$18.55M	-$16.75M	-$34.44M
Income Tax	—	—	$0.00	$226.07K
Net Income	-$17.56M	-$18.55M	-$16.75M	-$34.66M
Diluted EPS	-1033233.41	-27313.84	-1336.63	-52.59
Diluted Shares	17	679	12558	689713

RNAZ Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.97M	$2.77M	$5.81M	$17.81M
Receivables	$360.23K	$0.00	$0.00	$953.10K
Current Assets	$7.38M	$4.46M	$7.09M	$21.98M
Total Assets	$7.59M	$5.17M	$7.29M	$162.40M
Current Liabilities	$4.35M	$3.49M	$2.77M	$3.49M
Total Debt	$0.00	$450.57K	$38.29K	$0.00
Total Liabilities	$4.35M	$3.53M	$9.31M	$10.52M
Retained Earnings	-$27.87M	-$46.42M	-$63.20M	-$97.86M
Shareholders' Equity	$3.24M	$1.64M	-$2.02M	$151.88M
Working Capital	$3.03M	$964.85K	$4.32M	$18.49M

RNAZ Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.76M	-$18.07M	-$13.34M	-$19.52M
Capital Expenditure	-$100.92K	-$35.61K	-$21.76K	-$6.66K
Free Cash Flow	-$15.86M	-$18.11M	-$13.36M	-$19.52M
Depreciation & Amortisation	$98.61K	$516.75K	$534.86K	$114.18K
Stock-Based Compensation	$395.33K	$1.04M	$1.70M	$485.43K
Investing Cash Flow	-$100.92K	-$35.61K	-$21.76K	-$4.44K
Financing Cash Flow	$5.99K	$15.91M	$16.40M	$31.52M
Net Change in Cash	-$15.86M	-$2.20M	$3.04M	$12.00M

RNAZ Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.22M	$2.57M	$3.16M	$5.48M	$15.53M	$3.69M
Selling, General & Admin	$951.65K	$1.66M	$1.40M	$1.76M	$2.22M	$2.54M
Operating Expenses	$2.82M	$4.07M	$4.54M	$6.49M	$17.62M	$6.21M
Operating Income	-$2.82M	-$4.07M	-$4.54M	-$6.49M	-$17.62M	-$6.21M
EBITDA	-$12.03M	-$4.26M	-$4.85M	-$13.17M	-$17.53M	-$6.73M
Pretax Income	-$12.09M	-$4.28M	-$4.86M	-$13.22M	-$17.55M	-$6.75M
Income Tax	$0.00	$0.00	—	—	$231.31K	$300.00
Net Income	-$12.09M	-$4.28M	-$4.86M	-$13.44M	-$17.79M	-$6.75M
Diluted EPS	-70.16	-5.13	-5.82	—	-21.28	-7.17
Diluted Shares	172262	833653	834373	—	916968	957191

RNAZ Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$11.57M	$7.37M	$2.84M	$17.81M	$12.84M	$8.38M
Receivables	$322.44K	$176.12K	$198.30K	$953.10K	$638.00	$638.00
Current Assets	$13.04M	$8.24M	$4.75M	$21.98M	$16.75M	$10.64M
Total Assets	$13.19M	$8.27M	$5.23M	$162.40M	$157.16M	$151.01M
Current Liabilities	$2.51M	$1.56M	$2.97M	$3.49M	$5.38M	$5.40M
Total Debt	$0.00	$0.00	$0.00	$0.00	—	$652.41K
Total Liabilities	$2.90M	$2.12M	$3.80M	$10.52M	$12.64M	$12.65M
Retained Earnings	-$75.29M	-$79.56M	-$84.42M	-$97.86M	-$115.65M	-$122.40M
Shareholders' Equity	$10.29M	$6.15M	$1.43M	$151.88M	$144.52M	$138.36M
Working Capital	$10.53M	$6.68M	$1.78M	$18.49M	$11.37M	$5.24M

RNAZ Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.10M	-$4.19M	-$4.08M	-$8.14M	-$4.98M	-$5.40M
Free Cash Flow	-$3.10M	-$4.19M	-$4.08M	-$8.15M	-$4.98M	-$5.40M
Depreciation & Amortisation	$51.17K	$13.44K	$4.78K	$44.78K	$23.94K	$23.94K
Stock-Based Compensation	$157.73K	$131.51K	$134.32K	$61.87K	$0.00	$0.00
Investing Cash Flow	$0.00	$0.00	$0.00	-$4.44K	—	—
Financing Cash Flow	$8.85M	$0.00	-$455.73K	$23.12M	$0.00	$950.00K
Net Change in Cash	$5.76M	-$4.19M	-$4.54M	$14.98M	-$4.98M	-$4.45M

Market Snapshot

About

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on developing RNA therapeutics for cancer treatment. The company utilizes its proprietary TTX nanoparticle platform to deliver therapeutic RNA to tumor cells, targeting metastatic disease. TransCode is advancing RNA-based therapies designed to address mechanisms that drive cancer progression and metastasis.